---
layout: post
title: "多瑞医药：盐酸文拉法辛缓释胶囊上市申请获受理"
date: 2021-12-30 20:06:20 +0800
categories: cailianshe
tags: 财联社新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.301075" data-code="301075|0|2" data-code2="301075|0|80|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.301075&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 301075_0" data-code="K 301075|0|2" data-code2="K 301075|0|80|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>多瑞医药公告，全资子公司湖北多瑞药业有限公司收到国家药监局下发的盐酸文拉法辛缓释胶囊药品注册受理通知书。文拉法辛由美国惠氏WYETH PHARMS INC(现与辉瑞合并)开发，用于治疗抑郁症(包括伴有焦虑的抑郁症)及广泛性焦虑障碍。<br /></p><p class="em_media">（文章来源：财联社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202112302231791975>

[返回财联社新闻](//finews.withounder.com/category/cailianshe.html)｜[返回首页](//finews.withounder.com/)